Browse TNFRSF9

Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF00020 TNFR/NGFR cysteine-rich region
Function

Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009306 protein secretion
GO:0032496 response to lipopolysaccharide
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032693 negative regulation of interleukin-10 production
GO:0032695 negative regulation of interleukin-12 production
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051224 negative regulation of protein transport
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0070206 protein trimerization
GO:0070207 protein homotrimerization
GO:0071356 cellular response to tumor necrosis factor
GO:0072608 interleukin-10 secretion
GO:0072610 interleukin-12 secretion
GO:0097191 extrinsic apoptotic signaling pathway
GO:1903531 negative regulation of secretion by cell
GO:1904950 negative regulation of establishment of protein localization
GO:2001179 regulation of interleukin-10 secretion
GO:2001180 negative regulation of interleukin-10 secretion
GO:2001182 regulation of interleukin-12 secretion
GO:2001183 negative regulation of interleukin-12 secretion
Molecular Function GO:0005031 tumor necrosis factor-activated receptor activity
GO:0005035 death receptor activity
GO:0019955 cytokine binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFRSF9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFRSF9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26773716Leukemia; LymphomaPromote immunityFurthermore, the signaling cytoplasmic tail of CD137 is a key component of anti-CD19 chimeric antigen receptors that are used to redirect T cells against leukemia and lymphoma in the clinic.
26493961MelanomaInhibit immunityMoreover, administration of systemic sFLT3L and local poly-ICLC enhanced DC-mediated cross-priming and synergized with anti-CD137- and anti-PD-1-mediated immunostimulation in tumor therapy against B16-ovalbumin-derived melanomas, whereas this function was lost in Batf3(-/-) mice.
26034288MelanomaPromote immunity (T cell function)Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
25893601Plasma Cell MyelomaPromote immunity (T cell function)Activation of costimulatory receptor CD137 with mAb (4-1BB) exerted strong antimyeloma activity, while inhibition of coinhibitory receptors PD-1 and CTLA-4 had no effect.
25601928Colon AdenocarcinomaPromote immunity (T cell function)In vivo 4-1BB deficiency in myeloid cells enhances peripheral T cell proliferation by increasing IL-15.
25472998MelanomaPromote immunity (infiltration)We found that addition of an agonistic anti-4-1BB antibody could activate 4-1BB signaling within early cultured tumor fragments and accelerated the rate of memory CD8(+) TIL outgrowth that were highly enriched for melanoma antigen specificity.
25387892MelanomaPromote immunity (T cell function)Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
24667641Metastatic MelanomaInhibit immunity (T cell function)In all 6 tumors studied, expression of the inhibitory receptors programmed cell death 1 (PD-1; also known as CD279), lymphocyte-activation gene 3 (LAG-3; also known as CD223), and T cell immunoglobulin and mucin domain 3 (TIM-3) on CD8? TILs identified the autologous tumor-reactive repertoire, including mutated neoantigen-specific CD8? lymphocytes, whereas only a fraction of the tumor-reactive population expressed the costimulatory receptor 4-1BB (also known as CD137).
18364008Melanoma; Renal Cell Carcinoma; Ovarian Carcinoma; Non-Small Cell Lung CarcinomaPromote immunityThe promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. A number of different solid tumor types are being tested in these studies, including melanoma, renal cell carcinoma, ovarian carcinoma, and non‐small cell lung cancer. One receptor:ligand pair (4-1BB/CD137 and 4-1BBL/CD137L) is emerging as a target with important potential in its ability to enhance the generation of effective tumor-specific immune responses in situ.
28905118LymphomaImmunotherapy targetOverall intratumoral or peri-tDLN administration of the novel combination of anti-CTLA4, anti-CD137, and anti-OX40, all agents in the clinic or clinical trials, demonstrates potent systemic anti-tumor effects. This immunotherapeutic combination is promising for future clinical development via both these safe and highly efficacious routes of administration.
27267778MelanomaPromote immunityCombining TLR1-TLR2 ligand with an agonistic antibody to 4-1BB enhanced the antitumor activity in mice with established melanoma tumors. These studies reveal that the costimulatory effects of TLR1-TLR2 signaling in CD8(+) T cells are in part mediated by 4-1BB and are important for mounting an effective antitumor immune response. Cancer Immunol Res; 4(8); 708-16.
28473315Triple-Negative Breast CarcinomaPromote immunity (T cell function)4-1BB-Enhanced Expansion of CD8+TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+T Cells. This observation led us to hypothesize that CD8+TIL could be utilized in autologous adoptive cell therapy for TNBC, although this concept has proven to be challenging, given the difficulty in expanding CD8+TILs in solid cancers other than in melanoma. To overcome this obstacle, we used an agonistic antibody (urelumab) to a TNFR family member, 4-1BB/CD137, which is expressed by recently activated CD8+T cells.
23460536Prostate CarcinomaPromote immunityFood and Drug Administration approval of ipilumimab, an antibody that blocks the inhibitory action of CTLA-4, and clinical trials targeting 4-1BB and PD-1 or PD-L1, have underscored the therapeutic potential of using immunomodulatory antibodies to stimulate protective immunity in human patients. In a proof-of-concept study in mice, we have shown that an agonistic 4-1BB-binding aptamer conjugated to a prostate-specific membrane antigen (PSMA)-binding aptamer led to the inhibition of PSMA-expressing tumors, was more effective than, and synergized with, vaccination, and exhibited a superior therapeutic index compared with nontargeted costimulation with 4-1BB antibodies or 4-1BB aptamers.
23436794MelanomaPromote immunityImmunostimulatory agonists such as anti-CD137 and interleukin (IL)-2 have elicited potent antitumor immune responses in preclinical studies, but their clinical use is limited by inflammatory toxicities that result upon systemic administration. We anchored anti-CD137 and an engineered IL-2Fc fusion protein to the surfaces of PEGylated liposomes, whose physical size permitted dissemination in the tumor parenchyma and tumor-draining lymph nodes but blocked entry into the systemic circulation following intratumoral injection. In the B16F10 melanoma model, intratumoral liposome-coupled anti-CD137 + IL-2Fc therapy cured a majority of established primary tumors while avoiding the lethal inflammatory toxicities caused by equivalent intratumoral doses of soluble immunotherapy.
21266358Lung CarcinomaPromote immunity (T cell function)Agonist monoclonal antibodies (mAb) to the immune costimulatory molecule CD137, also known as 4-1BB, are presently in clinical trials for cancer treatment on the basis of their costimulatory effects on primed T cells and perhaps other cells of the immune system.
19641184LymphomaPromote immunity (T cell function)Anti-CD137 agonistic mAb has demonstrated antitumor efficacy in various tumor models and has now entered clinical trials for the treatment of solid tumors. The antitumor effect of anti-CD137 therapy was mediated by both natural killer (NK) and CD8 T cells and induced long-lasting immunity.
16680149Breast Carcinoma; Renal Cell Carcinoma; Colon Carcinoma; Lung CarcinomaPromote immunity (T cell function)Here we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand (TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8+ T cells capable of eradicating preestablished tumors. This combination therapy of three monoclonal antibodies (trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon (IFN)-gamma in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-gamma in the tumor rejection process.
27496866Head and Neck CarcinomaPromote immunity (NK cell function)CD137 agonist mAb urelumab enhanced cetuximab-activated NK-cell survival, DC maturation, and tumor antigen cross-presentation. Urelumab boosted DC maturation markers, CD86 and HLA DR, and antigen-processing machinery (APM) components TAP1/2, leading to increased tumor antigen cross-presentation. These results suggest a beneficial effect of combination immunotherapy using cetuximab and CD137 agonist in HNC.
23754772MelanomaPromote immunity (T cell function); essential for immunotherapyTo that end, T cells purified from healthy donors and from vaccinated-melanoma patients were transduced to express high levels of constitutive 4-1BB. In addition, these cells expanded and proliferated at a higher rate, expressed heightened levels of the antiapoptotic molecule Bcl(XL) and were also relatively insensitive to immunosuppression mediated by transforming growth factor-β, compared to control cells. We also show that 4-1BBL expression on the target cell is essential to 4-1BB-mediated functional improvement. Overall, we conclude that the modification of human T cells with 4-1BB yields enhanced antitumor function which may have important applications in therapies based on the genetic modification of patient lymphocytes.
23649004NeuroblastomaInhibit immunity (T and NK cell function); immunotherapy targetIn the Neuro2a model, treatment of established tumor with anti-4-1BB, anti-CD40, or anti-CTLA-4 mAb results in tumor regression and long-term survival in 40% to 60% of mice. This is dependent on natural killer (NK) and CD8(+) T cells and is associated with tumor CD8(+) lymphocyte infiltrate. These data suggest that the combination of antigen and costimulatory mAb may provide effective immunotherapy against neuroblastoma and may be of particular use in the minimal residual disease setting.
17332366MelanomaInhibit immunity (NK cell function); immunotherapy targetWe further show that the percentage of NK cells was higher in B16-1D8 melanomas expressing anti-CD137 scFv than in the WT tumors and that the percentage of FoxP3(+) cells was lower. Admixture of 10% K1735-1D8 cells prevented the progressive growth of transplanted K1735-WT cells in syngeneic mice and also of cells from the antigenically different sarcoma Ag104.
24837434Head and Neck Carcinoma; Colorectal CarcinomaPromote immunity (T cell function)The costimulatory molecule CD137 (4-1BB) is expressed following NK and memory T cell activation. We found that isolated human NK cells substantially increased expression of CD137 when exposed to cetuximab-coated, EGFR-expressing HN and CRC cell lines. Furthermore, activation of CD137 with an agonistic mAb enhanced NK cell degranulation and cytotoxicity. In multiple murine xenograft models, including EGFR-expressing cancer cells, HN cells, and KRAS-WT and KRAS-mutant CRC, combined cetuximab and anti-CD137 mAb administration was synergistic and led to complete tumor resolution and prolonged survival, which was dependent on the presence of NK cells. In patients receiving cetuximab, the level of CD137 on circulating and intratumoral NK cells was dependent on postcetuximab time and host FcyRIIIa polymorphism. Interestingly, the increase in CD137-expressing NK cells directly correlated to an increase in EGFR-specific CD8+ T cells.
24789574Hepatocellular CarcinomaPromote immunity (T cell function)We assessed the therapeutic effects of stimulating CD137, a member of the TNF receptor family, with agonistic monoclonal antibodies (mAb). In an orthotopic HCC the treatment consistently leads to complete tumor regression in 40-60% of animals. The protection is long lasting in the animals responding to the treatment, which can reject a second tumor challenge more than 3 months after treatment and eradication of the first malignancy. The efficacy of anti-CD137 mAb treatment is associated with early, sustained recruitment of iNOS-positive macrophages within tumor nodules. Moreover, in the absence of treatment, tumor development is accompanied by infiltration by myeloid derived suppressor cells (MDSC) and regulatory T lymphocytes. In mice responding to the anti-CD137 mAb treatment, this infiltration is very limited, and a combination treatment with a depletion of MDSC leads to the recovery of 80% of the mice.
19190115MelanomaInhibit immunity (T cell function)Anti-4-1BB protected na?ve T cells from CTX and promoted proliferation of memory/effector and memory T cells. The combination treatment produced approximately 60- and 2.2-fold more CTLs per tumor-associated antigen compared with CTX or anti-4-1BB alone, respectively. This indicates that anti-4-1BB promoted a preferential expansion of tumor-specific CD8(+) T cells among the repopulated lymphocytes following CTX-mediated lymphopenia. CTX treatment enhanced 4-1BB expression on CD4 and CD8 T cells, and CTX alone or in combination with anti-4-1BB effectively suppressed peripheral regulatory T cells.
17170077Acute Myeloid LeukemiaPromote immunity (T cell function)Addition of 4-1BBL to cocultures of AML-DC and T cells induced a preferential increase in the proliferation of CD8(+) T cells. Increased differentiation into effector and central memory populations was observed in both CD4(+) and CD8(+) T cells in the presence of 4-1BBL. AML-DC induce a T helper 1 response, characterized by high IFN-gamma production, which is significantly increased by targeting 4-1BB.
29678874melanomaPromote immunity (T cell function); increase the efficacy of immunotherapyCollectively, these data point to a critical link between mitochondrial morphology and function and enhanced antitumor effector activity upon CD137 costimulation of T cells.
29632708hepatocellular carcinomaInhibit immunity (T cell function); immunotherapy targetHere, we found that anti-CD137 monoclonal antibody (mAb) treatment in mice induced the infiltration of a large number of S100A4+ macrophages into the liver.
24045181Ovarian Cancinoma; MelanomaPromote immunity (T cell function)Upregulation of CD137 (4-1BB) on recently activated CD8(+) T cells has been used to identify rare viral or tumor antigen-specific T cells from peripheral blood. CD137(pos) TILs also mediated superior antitumor effects in vivo, compared with CD137(neg) TILs. An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzyme-digested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2. Enriched CD137(pos) TILs, but not PD-1(pos) or PD-1(neg) CD137(neg) cells, possessed autologous tumor reactivity in vitro and in vivo.
24030703Hepatocellular CarcinomaInhibit immunity (T cell function)Anti-B7-H1 (PD-L1) monoclonal antibodies (mAb) block a critical inhibitory pathway in T cells, whereas anti-CD137 and OX40 mAbs provide T-cell costimulation.
23975756Ovarian CancinomaPromote immunity (T cell function)When combined with GVAX or FVAX vaccination (consisting of irradiated ID8 cells expressing granulocyte macrophage colony-stimulating factor or FLT3 ligand) and costimulation by agonistic α-4-1BB or TLR 9 ligand, antibody-mediated blockade of PD-1 or PD-L1 triggered rejection of ID8 tumors in 75% of tumor-bearing mice. This therapeutic effect was associated with increased proliferation and function of tumor antigen-specific effector CD8(+) T cells, inhibition of suppressive regulatory T cells (Treg) and MDSC, upregulation of effector T-cell signaling molecules, and generation of T memory precursor cells.
21482773Breast Carcinoma (ERBB-(+))Inhibit immunity (T/NK cell function); immunotherapy targetFinally, we investigated whether immunostimulatory approaches with antibodies against programmed death-1 (PD-1) or 41BB (CD137) could be used to capitalize on the immune-mediated effects of trastuzumab. We demonstrate that anti-PD-1 or anti-CD137 mAb can significantly improve the therapeutic activity of anti-ErbB-2 mAb in immunocompetent mice.
22735380Melanoma; Lung CarcinomaImmunotherapy targetIn this study, we provide evidence for powerful synergistic effects of a combined strategy consisting of intratumoral injection of SFV-IL-12 and systemic delivery of agonist anti-CD137 monoclonal antibodies (mAbs), which was substantiated against poorly immunogenic B16 melanomas (B16-OVA and B16.F10) and TC-1 lung carcinomas. Importantly, we found that SFV-IL-12 intratumoral injection induces bright expression of CD137 on most tumor-infiltrating CD8(+) T lymphocytes, thereby providing more abundant targets for the action of the agonist antibody.
22232735LymphomaInhibit immunityIn a murine model of B-cell lymphoma, only CD137(neg)CD44(hi) CD4 T cells infiltrated tumor sites and provided protection. Conversely, the population of CD137(pos)CD44hi CD4 T cells consisted primarily of activated T(regs). Moreover, in vitro these CD137(pos) cells suppressed the proliferation of effector cells in a contact-dependent manner, and in vivo adding the CD137(pos)CD44(hi) CD4 cells to CD137(neg)CD44(hi) CD4 cells suppressed the antitumor immune response. Thus, CD137 expression on CD4 T cells defined a population of activated T(regs) that greatly limited antitumor immune responses.
21546571Ovarian CarcinomaPromote immunity; Essential for immunotherapyIn vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Our results show that anti-FRα CAR outfitted with CD137 costimulatory signaling in tandem overcome issues of T-cell persistence and tumor localization that limit the conventional FRα T-cell targeting strategy to provide potent antitumor activity in vivo.
18980984Plasma Cell MyelomaInhibit immunity; Immunotherapy targetAnti-CD137 mAbs induced complete eradications of established s.c. NS0-derived tumors that were dependent on IFN-gamma, natural killer cells, and CD8(+) T lymphocytes. Natural killer cells accumulated in tumor draining lymph nodes and showed increased IFN-gamma production.
23204227lymphomaPromote immunityOur results reveal a new regulatory mechanism for CD137L expression that mediates immune escape by HRS cells, and they identify CD137 as a candidate target for immunotherapy of Hodgkin lymphoma. Disappearance of CD137L from the surface of HRS and antigen-presenting cells led to reduced costimulation of T cells through CD137, reducing IFN-gamma release and proliferation.
16931626leukemia; renal cell carcinomaPromote immunityIn vitro expansion of tumor-reactive T cells followed by CD137-mediated SAD might enhance the antitumor efficacy of T-cell allografts with lower risk of inducing GVHD
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFRSF9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFRSF9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0520.894
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1940.773
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2340.683
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1870.679
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6740.444
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4330.69
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1860.122
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6090.163
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7490.543
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8270.386
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0590.965
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2210.342
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFRSF9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFRSF9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFRSF9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFRSF9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFRSF9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFRSF9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFRSF9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFRSF9
Nametumor necrosis factor receptor superfamily, member 9
Aliases CD137; 4-1BB; ILA; CDw137; 4-1BB ligand receptor; CD137 antigen; T cell antigen ILA; T-cell antigen 4-1BB ho ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFRSF9 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.